Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
about
Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsRationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline DataEffects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisNovel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.The renal effects of SGLT2 inhibitors and a mini-review of the literature.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisAssociation of Whole Blood Viscosity With Metabolic Syndrome in Type 2 Diabetic Patients: Independent Association With Post-Breakfast TriglyceridemiaRationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.Impact of empagliflozin in patients with diabetes and heart failure.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.SGLT2 Inhibitors: Benefit/Risk Balance.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
P2860
Q28072339-0FFAA286-73D3-4052-A6A4-2E0DD714DC35Q28072939-C4D1B5D0-13BE-432B-8CA6-CFCF2EDAA135Q28553482-3237F14E-48DB-45A0-85FF-C49AC1EC9928Q30248634-92D64131-04CA-41A3-A8F3-4C23CA4AA9FFQ31112303-95F379D3-7856-4ACA-A111-E54FE1E15E48Q33556240-4C5940B1-57A2-468C-A169-CE83E78A7E46Q33727891-567910E3-B5FE-4916-B1C8-50F4669846ADQ33763316-40A2C455-C260-4595-A985-66CA77730A7DQ33767478-B8514B97-73FA-4CF9-9349-2AF04F09EE27Q33835709-BB2724FF-9374-44F8-AC39-96043597D12DQ33835824-8514B0EE-CFE5-4334-8727-A0CBCC12DE4CQ33845734-82AAE045-7662-4589-9260-B899BAAA5A48Q33913060-E11DB917-4BAD-46D6-80AE-C1601EA1E047Q36096350-93838642-7ED3-4AFC-BB32-D9C5ED75B671Q37251449-62622522-F536-4694-99B5-6CF8D6EC330EQ37620904-F3B1E2C5-1B30-4BE7-808E-0D13BA011152Q37632127-D485EED8-6CEB-4AA8-AF80-317DC7261AB4Q37661798-E2CE705B-E588-46BE-B5E0-2EEF36FF724DQ37668253-D6F5F936-43CC-4B68-8939-0D52E61C093FQ37672170-62CA2870-6F89-4804-BA2D-63279CBE3076Q37697744-4464FFCA-080B-42A5-B791-1DCFA061F8BEQ38371417-80F2D4FF-F4FF-4F18-B493-96CFEDD80E37Q38383470-03B75288-3926-476D-8FC4-B7A8B4BCF818Q38614488-CBAFC307-B109-4F75-84E0-44A3E980AC32Q38635763-2AA7AB97-BBCD-4E7F-B476-D7901D84126FQ38645792-40F39B23-A01C-4C16-871E-89C17B7C6FC1Q38654762-94325B70-9F63-4A7B-8ECB-F25E2A468DF5Q38744467-418B7286-B5B3-4850-AF29-658FCAF039CBQ38802437-C3F4B921-4CDF-4221-B7BC-0C194F091EAFQ38822815-1A81361C-55DA-4363-8204-FEB0BFBE861CQ38824557-11B5CB4A-5656-453E-8B61-0F269C73164BQ38842559-478B7DB7-E556-4938-A6D4-C5B325E71C50Q38907817-C058D890-A295-4C12-BB19-EF2DD342F7D5Q38918743-94B113A8-5D88-4252-9068-E3409CFD959DQ38931842-8BE8BF49-E523-4CB5-AAF9-0C50E54B3825Q38932322-7A0AFB3B-07CA-40AA-8456-52CA1DBAF47BQ38940175-2088738B-EECB-491E-A0FD-BEAF8BC8E028Q39003573-4579A5AE-1F4C-4EBB-94F8-DBB6E4A4FD06Q39126658-FA19A79D-A053-4186-852E-AE218F7B8657Q39189383-945977D2-BAC3-4E74-8921-A2816A1B4827
P2860
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@ast
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@en
type
label
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@ast
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@en
prefLabel
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@ast
Effects of sodium-glucose cotr ...... atic review and meta-analysis.
@en
P2093
P50
P1476
Effects of sodium-glucose cotr ...... matic review and meta-analysis
@en
P2093
Celine Foote
Juuso Blomster
Tadashi Toyama
Vlado Perkovic
P304
P356
10.1016/S2213-8587(16)00052-8
P577
2016-03-18T00:00:00Z